EIKN
Eikon Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$10.96
+0.00%Aug 13, 2026, 20:02 UTC
Eikon Therapeutics reported its financial results for the second quarter of 2026 and provided clinical program updates on August 13, 2026.
Source:Jul 27, 2026, 11:30 UTC
Eikon Therapeutics dosed the first patient in a Phase 2/3 trial of EIK1001 for non-small cell lung cancer.
Source:Jun 10, 2026, 00:00 UTC
Ma. Fatima D. Francisco was appointed as a Class I director and member of the Compensation Committee of Eikon Therapeutics, Inc., effective June 15, 2026, with an option to purchase 85,937 shares of common stock at $8.96 per share vesting in 48 equal monthly installments.